Skip to main content
. Author manuscript; available in PMC: 2020 May 19.
Published in final edited form as: J Med Primatol. 2019 Oct 1;49(1):26–33. doi: 10.1111/jmp.12438

Figure 1. Pharmacokinetic of BCL6 BTB inhibitor (FX1) in uninfected rhesus macaques and mice.

Figure 1.

(A) Schematic diagram of the experimental design. Two Indian rhesus macaques received one dose of FX1 at 25mg/kg S.Q. and then underwent five blood collection at 0, 2,4,6 and 24hr later. 18 CD-1 mice received on FX1 at 25mg/kg I.P. and then underwent six blood collections with each collection including three mice at 0.5, 2,4,6, 8 and 24hr later. Additional 3 CD-1 mice received vehicle were used for collecting blood at 24hr later as the negative control. (B) The plasma FX1 concentrations measured at 0, 0.5, 2, 4, 6, 8 and 24hr after one dose of FX1 injection were presented. (C) The FX1 exposure level in mice and macaques was calculated using the area under the curve (AUC) and presented. Mean and standard error were indicated in panel B and C.